Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00773747Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- Sep 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Vorinostat + Bortezomib with Placebo + Bortezomib (2 arms). Primary endpoint: Progression-Free Survival at 32 months. Started Dec 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00773747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773747.